QLS5132 Goes after CLDN6 in Ovarian Cancer
Jun 1, 2026 · For patients with advanced platinum-resistant ovarian cancer, treatment options remain limited, but new agents are emerging. One is QLS5132, an antibody–drug conjugate targeting …
QLS5132 Goes after CLDN6 in Ovarian Cancer - PubMed
Jun 1, 2026 · For patients with advanced platinum-resistant ovarian cancer, treatment options remain limited, but new agents are emerging. One is QLS5132, an antibody-drug conjugate targeting …
AACR 2026: QLS5132, a CLDN6-Targeted ADC, Demonstrates Clinical …
Apr 19, 2026 · Patients treated with QLS5132, a novel antibody-drug conjugate (ADC) developed by Qilu Pharmaceutical Co. experienced clinical benefit. This conclusion is based on results from a …
AACR 2026: QLS5132, a CLDN6-Targeted ADC, Demonstrates Clinical …
Apr 19, 2026 · The current results support further clinical development of QLS5132, both as monotherapy and in combination regimens for patients with CLDN6-positive or heterogeneous PROC.
New Antibody-drug Conjugate Shows Clinical Benefit for Advanced ...
Apr 19, 2026 · Zhu and collaborators tested an investigational ADC, QLS5132, which targets the protein CLDN6. QLS5132 combines a CLDN6-targeting monoclonal antibody with a cytotoxic payload, …
QLS5132 - ADC Review
In early clinical trials QLS5132 was well-tolerated under potential recommended dose levels (<6.4 mg/kg) and presented remarkable antitumor activity in pts with advanced Platinum-resistant ovarian …
Prof. Zhu Tao: QLS5132 First-in-Human Study Shows Efficacy & Safety ...
May 20, 2026 · As a next-generation CLDN6-targeting ADC, QLS5132 has demonstrated breakthrough preliminary clinical data in PROC, bringing new hope to an area of significant unmet need and laying …
Abstract CT037: A first-in-human phase 1 trial of a novel claudin 6 ...
May 15, 2026 · QLS5132 showed response regardless of baseline CLDN6 expression. After multiple administrations, the CA125 levels in most pts showed a decreasing trend compared with baseline.
CLDN6-Targeted ADC QLS5132 Shows Promising Activity in Platinum ...
Apr 27, 2026 · Treatment with the novel Claudin 6 (CLDN6)–directed antibody-drug conjugate (ADC) QLS5132 led to encouraging activity not hindered by safety in patients with platinum-resistant …
QLS5132, a CLDN6-Targeting ADC from Qilu Pharmaceutical, …
On April 21, Qilu Pharmaceutical announced that the latest clinical research data of its innovative drug QLS5132 had been presented in an oral report at the 2026 American Association for Cancer …